152 related articles for article (PubMed ID: 34559904)
1. Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017.
Dores GM; Curtis RE; Linet MS; Morton LM
Am J Hematol; 2021 Dec; 96(12):E451-E454. PubMed ID: 34559904
[No Abstract] [Full Text] [Related]
2. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series.
Smith CJ; Thomas JW; Ruan G; Hyun MC; Bansal R; McLaughlin N; Pardanani A; Gangat N; Go RS; Szuber N; Goyal G; Shah MV; Tefferi A
Am J Hematol; 2021 Dec; 96(12):E464-E468. PubMed ID: 34661932
[No Abstract] [Full Text] [Related]
3. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Mora B; Giorgino T; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Barraco D; Merli M; Pietra D; Casalone R; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Passamonti F
Haematologica; 2018 Sep; 103(9):e392-e394. PubMed ID: 29622658
[No Abstract] [Full Text] [Related]
4. Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.
Wanquet A; Courtier F; Guille A; Carbuccia N; Garnier S; Adélaide J; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Birnbaum D; Murati A
Leuk Lymphoma; 2019 May; 60(5):1289-1293. PubMed ID: 30601073
[No Abstract] [Full Text] [Related]
5. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.
Johansson P
Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273
[TBL] [Abstract][Full Text] [Related]
6. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
Barraco D; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Merli M; Pietra D; Barbui T; Rotunno G; Cazzola M; Giorgino T; Vannucchi AM; Passamonti F
Blood Cancer J; 2018 Sep; 8(10):89. PubMed ID: 30291232
[No Abstract] [Full Text] [Related]
7. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
8. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
10. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
12. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Tam CS; Kantarjian H; Cortes J; Lynn A; Pierce S; Zhou L; Keating MJ; Thomas DA; Verstovsek S
J Clin Oncol; 2009 Nov; 27(33):5587-93. PubMed ID: 19786661
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
14. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.
Heppner J; Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
BMC Res Notes; 2019 May; 12(1):286. PubMed ID: 31126326
[TBL] [Abstract][Full Text] [Related]
15. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
[TBL] [Abstract][Full Text] [Related]
16. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
17. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
18. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
19. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
[TBL] [Abstract][Full Text] [Related]
20. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
